-
Aromatherapy for HSCT Distress
Not Recruiting
More
The purpose of this research is to evaluate aromatherapy inhaler use and how it may impact
cancer distress and coping by patients in the first few days after hematopoietic stem cell
transplant (HSCT).
Stanford is currently not accepting patients for this trial.
For more information, please contact SPECTRUM, .
Lead Sponsor
Stanford Investigators
View full details
-
Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies
Recruiting
More
The primary purpose of this study is to test whether CD22-CAR T cells can be successfully
made from immune cells collected from adults with relapsed/refractory B-cell malignancies
(leukemia and lymphoma).
Lead Sponsor
Stanford Investigators
View full details
-
Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies
Not Recruiting
More
Omidubicel is an investigational therapy for patients with high-risk hematologic
malignancies.
Stanford is currently not accepting patients for this trial.
For more information, please contact Andrew Rezvani,, MD, 650-498-6000.
Stanford Investigators
View full details
-
TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801)
Not Recruiting
More
1703: The study is designed as a randomized, phase III, multicenter trial comparing two acute
graft-versus-host disease (aGVHD) prophylaxis regimens: tacrolimus/methotrexate (Tac/MTX)
versus post-transplant cyclophosphamide/tacrolimus/mycophenolate mofetil (PTCy/Tac/MMF) in
the setting of reduced intensity conditioning (RIC) allogeneic peripheral blood stem cell
(PBSC) transplantation.
1801: The goal of this protocol is to test the primary hypothesis that the engraftment stool
microbiome diversity predicts one-year non-relapse mortality in patients undergoing reduced
intensity allogeneic HCT.
Stanford is currently not accepting patients for this trial.
For more information, please contact Sivan Yani, 650-497-0330.
Stanford Investigators
View full details
-
Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS
Not Recruiting
More
This study is an open-label, controlled, multicenter, international, Phase III, randomized
study of transplantation of NiCord® versus transplantation of one or two unmanipulated,
unrelated cord blood units in patients with acute lymphoblastic leukemia or acute myeloid
leukemia, myelodysplastic syndrome, chronic myeloid leukemia or lymphoma, all with required
disease features rendering them eligible for allogeneic transplantation.
Stanford is currently not accepting patients for this trial.
For more information, please contact Andrew Rezvani,, MD, 650-498-6000.
Stanford Investigators
View full details
-
MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLC
Recruiting
More
This first time in human study is intended for men and women at least 18 years of age who
have advanced lung cancer which has grown or returned after being treated. In particular, it
is a study for subjects who have a blood test positive for HLA-A*02:01 and/or HLA-A*02:06 and
a tumor test positive for MAGE A10 protein expression (protein or gene). This trial is a dose
escalation trial that will evaluate 3 doses of transduced cells administered after a
lymphodepleting chemotherapy regimen using a 3+3 dose escalation design .The study will take
the subject's T cells, which are a natural type of immune cell in the blood, and send them to
a laboratory to be modified. The changed T cells used in this study will be the subject's own
T cells that have been genetically changed with the aim of attacking and destroying cancer
cells.
When the MAGE A10ᶜ⁷⁹⁶T cells are available, subjects will receive lymphodepleting
chemotherapy with cyclophosphamide and fludarabine, followed by the T cell infusion. The
purpose of this study is to test the safety of genetically changed T cells and find out what
effects, if any, they have in subjects with lung cancer. The study will evaluate three
different cell dose levels in order to find out the target cell dose. Once the target cell
dose is determined, additional subjects will be enrolled to further test the safety and
effects at this cell dose.
Subjects will be seen frequently by the Study Physician right after receiving their T cells
back and up to first 6 months. After that, subjects will be seen every three months. Subjects
will be seen every 6 months by their Study Physician for the first 5 years after the T cell
infusion. If the T cells are found in the blood at five years, then the subjects will
continue to be seen once a year until the T cells are no longer found in the blood for a
maximum of 15 years. If the T cells are no longer found in the blood at 5 years, then the
subject will be contacted by the Study Physician for the next 10 years. Subjects who have a
confirmed response or clinical benefit ≥4 weeks after the first T-cell infusion and whose
tumor continues to express the appropriate antigen target may be eligible for a second
infusion. All subjects, completing or withdrawing from the Interventional Phase of the study,
will enter a 15-year long-term follow-up phase for observation of delayed adverse events. All
subjects will continue to be followed for overall survival during the long-term follow-up
phase.
Stanford Investigators
View full details
-
A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)
Not Recruiting
More
The purpose of this study is to compare relapse-free survival between participants with
FLT3/ITD AML in first morphologic complete remission (CR1) who undergo hematopoietic stem
cell transplant (HCT) and are randomized to receive gilteritinib or placebo beginning after
the time of engraftment for a two year period.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies
Not Recruiting
More
The primary objective of this protocol is to provide expanded access to tabelecleucel to
participants with Epstein-Barr virus-associated diseases and malignancies for whom there are
no other appropriate therapeutic options, and who are not eligible to enroll in clinical
studies designed to support the development and registration of tabelecleucel.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant
Not Recruiting
More
This phase II trial studies how well ibrutinib works in preventing acute leukemia in patients
after reduced-intensity conditioning and stem cell transplant. Ibrutinib may stop the growth
of tumor cells by blocking some of the enzymes needed for cell growth.
Stanford is currently not accepting patients for this trial.
For more information, please contact Courtney Greene, 650-723-0387.
Stanford Investigators
View full details
-
CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies
Not Recruiting
More
This phase I trial studies the side effects of CD19/CD22 chimeric antigen receptor (CAR) T
cells when given together with chemotherapy and NKTR-255, and to see how well they work in
treating patients with CD19 positive B acute lymphoblastic leukemia that has come back or
does not respond to treatment. A CAR is a genetically-engineered receptor made so that immune
cells (T cells) can attack cancer cells by recognizing and responding to the CD19/CD22
proteins. These proteins are commonly found on diffuse large B-cell lymphoma and B acute
lymphoblastic leukemia. Drugs used in chemotherapy, such as cyclophosphamide and fludarabine
phosphate, work in different ways to stop the growth of cancer cells, either by killing the
cells, by stopping them from dividing, or by stopping them from spreading. NKTR-255 is an
investigational IL-15 receptor agonist designed to boost the immune system's natural ability
to fight cancer. Giving CD19/CD22-CAR T cells and chemotherapy in combination with NKTR-255
may work better in treating patients with diffuse large B-cell lymphoma or B acute
lymphoblastic leukemia.
Stanford is currently not accepting patients for this trial.
For more information, please contact Matthew Abramian, 650-736-3351.
Stanford Investigators
View full details
-
Axicabtagene Ciloleucel Expanded Access Study
Not Recruiting
More
A multicenter, open-label expanded access protocol for the treatment of subjects with
relapsed/refractory large B-cell lymphoma.
Subjects who received an infusion of axicabtagene ciloleucel will complete the remainder of
the 15 year follow-up assessments in a separate long-term follow-up study, KT-US-982-5968
Stanford is currently not accepting patients for this trial.
For more information, please contact Julianna Craig, .
Stanford Investigators
View full details
-
Obinutuzumab in cGVHD After Allogeneic Peripheral Blood Stem Cell Transplantation
Not Recruiting
More
This research study is studying a drug called obinutuzumab as a means of preventing chronic
Graft vs. Host Disease (cGVHD).
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Donor Regulatory T Cells in Treating Patients With Visceral Acute Graft-versus-Host Disease After Stem Cell Transplant
Not Recruiting
More
This phase I trial studies the side effects and best dose of donor regulatory T cells in
treating patients with graft-versus-host disease affecting the liver or gastrointestinal
organs (visceral) within 100 days (acute) after undergoing a stem cell transplant.
Graft-versus-host disease occurs when donor immune cells infused in a stem cell transplant
attack the gut, skin, liver, or other organ systems of the patient. Regulatory T cells are a
type of immune cell that may be able to reduce the attack of the donor's immune cells on the
patient's normal cells and help treat graft-vs-host disease.
Stanford is currently not accepting patients for this trial.
For more information, please contact Joanne Otani, 650-721-2372.
Stanford Investigators
View full details
-
Fructooligosaccharides in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant
Not Recruiting
More
This pilot phase I trial studies the side effects and best dose of fructooligosaccharides in
treating patients with blood cancer who are undergoing donor stem cell transplant. Sometimes
the transplanted cells from a donor can make an immune response against the body's normal
cells (called graft-versus-host disease). Nutritional supplements such as
fructooligosaccharides may reduce the incidence of graft-versus-host disease in patients with
blood cancer undergoing donor stem cell transplant.
Stanford is currently not accepting patients for this trial.
For more information, please contact Courtney Greene, 650-723-0387.
Lead Sponsor
Stanford Investigators
View full details
-
Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors
Not Recruiting
More
This randomized phase III trial studies how well standard-dose combination chemotherapy works
compared to high-dose combination chemotherapy and stem cell transplant in treating patients
with germ cell tumors that have returned after a period of improvement or did not respond to
treatment. Drugs used in chemotherapy, such as paclitaxel, ifosfamide, cisplatin,
carboplatin, and etoposide, work in different ways to stop the growth of tumor cells, either
by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Giving chemotherapy before a stem cell transplant stops the growth of cancer cells by
stopping them from dividing or killing them. Giving colony-stimulating factors, such as
filgrastim or pegfilgrastim, and certain chemotherapy drugs, helps stem cells move from the
bone marrow to the blood so they can be collected and stored. Chemotherapy is then given to
prepare the bone marrow for the stem cell transplant. The stem cells are then returned to the
patient to replace the blood-forming cells that were destroyed by the chemotherapy. It is not
yet known whether high-dose combination chemotherapy and stem cell transplant are more
effective than standard-dose combination chemotherapy in treating patients with refractory or
relapsed germ cell tumors.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host Disease
Not Recruiting
More
The purpose of this study is to assess the safety and clinical efficacy of ibrutinib in
subjects with steroid dependent or refractory Chronic Graft Versus Host Disease.
Stanford is currently not accepting patients for this trial.
For more information, please contact Janet McDowell, 650-725-1647.
Stanford Investigators
View full details
-
Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Not Recruiting
More
The primary objective of phase 1 is to evaluate the safety of KTE-C19 and atezolizumab
combination regimens.
The primary objective of phase 2 is to evaluate the efficacy of KTE-C19 and atezolizumab, as
measured by complete response rate in participants with refractory diffuse large B-cell
lymphoma (DLBCL).
Subjects who received an infusion of KTE-C19 will complete the remainder of the 15 year
follow-up assessments in a separate long-term follow-up study, KT-US-982-5968
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Not Recruiting
More
This study is an access and distribution protocol for unlicensed cryopreserved cord blood
units (CBUs) in pediatric and adult patients with hematologic malignancies and other
indications.
Stanford is currently not accepting patients for this trial.
For more information, please contact Sandhya Kharbanda, MD, .
Stanford Investigators
View full details
-
Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant
Recruiting
More
This phase II trial studies how well ibrutinib works in treating patients after a donor stem
cell transplant for lymphoma that is not responding to treatment or has come back. Ibrutinib
may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Stanford Investigators
View full details
-
Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma
Not Recruiting
More
The goal of this clinical study is to assess whether axicabtagene ciloleucel therapy improves
the clinical outcome compared with standard of care second-line therapy in patients with
relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Donor Umbilical Cord Blood Transplant With or Without Ex-vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes
Not Recruiting
More
This randomized phase II trial studies how well donor umbilical cord blood transplant with or
without ex-vivo expanded cord blood progenitor cells works in treating patients with acute
myeloid leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, or
myelodysplastic syndromes. Giving chemotherapy and total-body irradiation before a donor
umbilical cord blood transplant helps stop the growth of cancer cells. It may also stop the
patient's immune system from rejecting the donor's cells. When the healthy stem cells and
ex-vivo expanded cord blood progenitor cells are infused into the patient they may help the
patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. It
is not yet known whether giving donor umbilical cord blood transplant plus ex-vivo expanded
cord blood progenitor cells is more effective than giving a donor umbilical cord blood
transplant alone.
Stanford is currently not accepting patients for this trial.
For more information, please contact Physician Referrals, 650-723-0822.
Stanford Investigators
View full details
-
Double Cord Versus Haploidentical (BMT CTN 1101)
Not Recruiting
More
Hematopoietic cell transplants (HCT)are one treatment option for people with leukemia or
lymphoma. Family members,unrelated donors or banked umbilical cordblood units with similar
tissue type can be used for HCT. This study will compare the effectiveness of two new types
of bone marrow transplants in people with leukemia or lymphoma: one that uses bone marrow
donated from family members with only partially matched bone marrow; and, one that uses two
partially matched cord blood units.
Stanford is currently not accepting patients for this trial.
For more information, please contact Physician Referrals, 650-723-0822.
Stanford Investigators
View full details
-
Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)
Not Recruiting
More
Acute Graft-versus-Host-Disease (GVHD) is an important cause of morbidity and mortality after
allogeneic hematopoietic stem cell transplantation (HSCT). This study aims to determine if
any of three new GVHD prophylaxis approaches improves the rate of GVHD and relapse free
survival at one year after transplant compared to the current standard prophylaxis regimen.
Stanford is currently not accepting patients for this trial.
For more information, please contact Physician Referrals, 650-723-0822.
Stanford Investigators
View full details
-
Bone Marrow Grafting for Leukemia and Lymphoma
Recruiting
More
The purpose of this study is to obtain tissue samples for ongoing studies regarding
transplant outcomes and complications.
Lead Sponsor
Stanford Investigators
View full details
-
Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation
Not Recruiting
More
This phase II trial studies donor atorvastatin treatment for the prevention of severe acute
graft-versus-host disease (GVHD) in patients undergoing myeloablative peripheral blood stem
cell (PBSC) transplantation. Giving chemotherapy and total-body irradiation (TBI) before a
donor PBSC transplant helps stop the growth of cancer cells. It may also prevent the
patient's immune system reject the donor's stem cells. When the healthy stem cells from a
donor are infused into the patient they may help the patient's bone marrow make stem cells,
red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a
donor can make an immune response against the body's normal cells. Giving atorvastatin to the
donor before transplant may prevent this from happening.
Stanford is currently not accepting patients for this trial.
For more information, please contact Leah Galvez, 650-725-7951.
Stanford Investigators
View full details
-
CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma
Not Recruiting
More
This phase 2 trial studies how well cluster of differentiation 8 (CD8)+ memory T-cells work
as a consolidative therapy following a donor non-myeloablative hematopoietic cell transplant
in treating patients with leukemia or lymphoma. Giving total lymphoid irradiation and
anti-thymocyte globulin before a donor hematopoietic cell transplant helps stop the growth of
cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells.
When the healthy stem cells from a donor are infused into the patient they may help the
patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets.
Sometimes the transplanted cells from a donor can make an immune response against the body's
normal cells (called graft-versus-host disease). Giving cyclosporine and mycophenolate
mofetil after the transplant may stop this from happening. Once the donated stem cells begin
working, the patient's immune system may see the remaining cancer cells as not belonging in
the patient's body and destroy them. Giving an infusion of the donor's white blood cells,
such as CD8+ memory T-cells, may boost this effect and may be an effective treatment to kill
any cancer cells that may be left in the body (consolidative therapy).
Stanford is currently not accepting patients for this trial.
For more information, please contact Leah Galvez, 650-725-7951.
Stanford Investigators
View full details
-
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1)
Not Recruiting
More
The purpose of this study was to assess the efficacy of ruxolitinib in combination with
corticosteroids in subjects with Grades II to IV steroid-refractory acute graft-versus-host
disease (GVHD).
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Safety Study of Cord Blood Units for Stem Cell Transplants
Recruiting
More
Background:
- Cord blood is blood that is taken from the umbilical cord and placenta of healthy newborns
after childbirth. The cord blood collected from a baby is called a cord blood unit. Cord
blood units are stored frozen in public cord blood banks. About 10,000 cord blood transplants
have been performed in children and adults for blood cancers and other diseases in the world.
These transplants have helped save lives and improve treatments. However, not all available
units of cord blood have been collected, stored, and licensed according to specific
government requirements. These unlicensed units can still be used in transplant, but they can
only be given as part of specific research studies. This study will evaluate the safety of
giving these unlicensed units by recording any problems that may occur during and after
giving the cord blood.
Objectives:
- To test the safety and effectiveness of unlicensed cord blood units in people who need stem
cell transplants.
Eligibility:
- Individuals who are scheduled to have a stem cell transplant.
Design:
- Participants will be screened with a medical history and physical exam.
- Participants will receive the cord blood unit as part of their stem cell transplant
procedure. The transplant will be performed according to the current standard of care
for the procedure.
- After the transplant, participants will be monitored for up to 1 year. Any problems or
side effects from the transplant will be treated as necessary. All outcomes will be
reported to the National Cord Blood Program and to the Center for International Blood
and Marrow Transplant.
Stanford Investigators
View full details
